Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a <i>GOPC::ROS1</i> fusion-Reference-Cited by-同舟云学术

Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a GOPC::ROS1 fusion

Published:2024-01-01 Issue:1 Volume:6 Page:
ISSN:2632-2498
Container-title:Neuro-Oncology Advances
language:en
Short-container-title:

Author:

Cerretti Giulia¹²^ORCID,Padovan Marta¹²,Guerriero Angela³,Maccari Marta²⁴,Bosio Alberto²⁴,Caccese Mario²,Cella Eugenia⁵,Pintacuda Giovanna⁶,Librizzi Giovanni⁷,Lombardi Giuseppe²^ORCID

Affiliation:

1. PhD course in Clinical and Experimental Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova , Padova, Italy

2. Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV—IRCCS , Padova, Italy

3. Surgical Pathology Unit, University Hospital of Padova , Padova , Italy

4. School of Specialization in Medical Oncology, Department of Surgery, Oncology and Gastroenterology, University of Padova , Padova, Italy

5. Oncology 2, IRCCS Ospedale San Martino , Genova , Italy

6. Radiology Unit, Veneto Institute of Oncology IOV – IRCCS

7. Department of Neuroscience, Azienda Ospedale-Università di Padova , Padova , Italy

Funder

Italian Ministry of Health

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdae077/57517192/vdae077.pdf

Reference25 articles.

1. Management of glioblastoma: state of the art and future directions;Tan;CA Cancer J Clin.,2020

2. Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis;Zeitlberger;J Neurooncol.,2022

3. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT);Mateo;Ann Oncol.,2018

4. Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making;Mj;Neuro-Oncology,2022

5. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis;Padovan;Eur J Cancer.,2023